Extracorporeal elimination of TNF-α-producing CD14 dullCD16+ monocytes in leukocytapheresis therapy for ulcerative colitis

Inflammatory Bowel Diseases

Volumn 13, Issue 3, 2007, Pages 284-290

  Kanai, Takanori ^a   Makita, Shin ^a   Kawamura, Takahiro ^a   Nemoto, Yasuhiro ^a   Kubota, Daisuke ^a   Nagayama, Kazuyoshi ^a   Totsuka, Teruji ^a   Watanabe, Mamoru ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

CD14dullCD16+ monocytes; Leukocytapheresis; Ulcerative colitis

Indexed keywords

CD14 ANTIGEN; CD16 ANTIGEN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTAPHERESIS; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; LEUKOCYTAPHERESIS; MALE; MONOCYTE; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; ANTIGENS, CD14; CD4-POSITIVE T-LYMPHOCYTES; COLITIS, ULCERATIVE; FEMALE; HUMANS; LEUKAPHERESIS; LEUKOCYTE COUNT; LEUKOCYTES, MONONUCLEAR; MALE; RECEPTORS, IGG; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947496270     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20017     Document Type: Article

References (31)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347: 417-429.
2. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
3. Singh B, Powrie F, MaC. Mortensen NJ. Immune therapy in inflammatory bowel disease and models of colitis. Br J Surg. 2001;88:1558-1569.
4. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 Study Group. N Engl J Med. 1997;337:1029-1035.
5. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340:1398-1405.
6. Pallone F, Monteleone G. Interleukin 12 and Th1 responses in inflammatory bowel disease. Gut. 1998;43:735-736.
7. Mannon PJ, Fuss IJ, Elson CO, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
8. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583-588.
9. Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology. 2004;126:989-996.
10. Hibi T, Sakuraba A. Is there a role for apheresis in gastrointestinal disorders? Nat Clin Pract Gastroenterol Hepatol. 2005;2:200-201.
11. Katz S. Update in medical therapy of ulcerative colitis: newer concepts and therapies. J Clin Gastroenterol. 2005;39:557-569.
12. Egan LJ, Sandborn WJ. Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis. Curr Gastroenterol Rep. 2005;7:485-491.
13. Sawada K, Ohnishi K, Fukui S, et al. Leukocytapheresis therapy, performed with leukocyte removal filter, for inflammatory bowel disease. J Gastroenterol. 1995;30:322-329.
14. Sawada K, Shimoyama T. Therapeutic cytaapheresis for inflammatory bowel disease. Ther Apher. 1998;2:90-92.
15. + regulatory T cells in human intestinal lamina propria. J Immunol. 2004;173:3119-3130.
16. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763.
17. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345-352.
18. high T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868-1878.
19. + regulatory. Semin Immunol. 2004;16:89.
20. Lowes JR, Jewell DP. The immunology of inflammatory bowel diseases. Springer Sem Immunopathol. 1990;12:251-268.
21. ++ monocytes are a major source of TNF. J Immunol. 2002;168:3536-3542.
22. Mannon PJ, Fuss IJ, Elson CO, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med. 2004;351:2069-2079.
23. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32:913-917.
24. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut. 1993;34:1705-1709.
25. Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet. 1992;339:89-91.
26. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353: 2462-2476.
27. +) subset of human monocytes preferentially becomes migratory dendritic cells in a model tissue setting. J Exp Med. 2002;196:517-527.
28. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology. 2001;121:1145-1157.
29. Van den Brande JM, Braat H, van den Brink et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology. 2003;124:1774-1785.
30. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) recptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151:1548-1561.
31. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2001;121:1088-1094.